We are excited to utilize the testing software from Cogstate for the Madison Memory Study
Madison, WI (Vocus) February 2, 2010
Quincy Bioscience is seeking men and women 40 years and older who are experiencing memory loss to enroll in a study that will evaluate the effects of the brain health supplement Prevagen® on cognitive function. The Prevagen Memory Study is a randomized placebo-controlled, double-blind study that will require five (5) visits for cognitive testing during the three (3) month study period. The impact of Prevagen on brain cell protection will be evaluated using computer-based cognitive testing software. The study is sponsored by Quincy Bioscience, the manufacturer of Prevagen®.
Quincy Bioscience is pleased to collaborate with Cogstate Ltd., a leading cognitive testing software company based in Melbourne, Australia. Cogstate’s proprietary computer-based testing software will be utilized to assess the effect of Prevagen on cognitive performance. “We are excited to utilize the testing software from Cogstate for the Madison Memory Study,” says Quincy Bioscience president Mark Underwood. “Cogstate is an industry leader with extensive research validating the use of its software tools for measuring cognitive effects.”
Prevagen® is the first and only product to use the active ingredient apoaequorin, a calcium-binding protein discovered in jellyfish. In university studies, Prevagen® was proven to protect brain cells.* First launched in in September of 2007, tens of thousands of people have taken Prevagen®.
Interested candidates who are able to travel to Madison, WI may visit Madison Memory Study to apply or call (608) 237-3170 for more information about the study.
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for dietary supplement and pharmaceutical products. The company’s first product, Prevagen was launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.
- These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.